ong delayed emesis induced by cancer chemotherapy can be suppressed by NK1 receptor antagonist (LODEC-N)

Not Applicable

Recruiting

• Conditions: antineoplastic combined chemotherapy regimens; Cancer chemotherapy; neurokinin-1 receptor antagonist; long delayed chemotherapy induced nausea and vomiting; D000971

• Registration Number: JPRN-jRCT1030230130
• Lead Sponsor: Seiichiro Kuroda

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

(i) written informed consent to participate in this study
(ii) patients undergoing chemotherapy and administered standard antiemetic therapy
(iii) age >18 years
(iv) male or female
(v) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1

Exclusion Criteria

(i) administration of low or minimal emetic risk rejimen
(ii) the use of opioids
(iii) patients with a history of habitual vomiting
(iv) brain metastasis having uncontrollable symptoms
(v) current radio therapy (within three months)
(vi) administration of chemotherapy within three months before enrolment
(vii) experienced nausea and vomiting within one week before enrollment
(viii) the current use of antiemetic agents within two week before enrollment
(ix) pregnant and lactating women

Study & Design

• Study Type: Observational
• Study Design: Not specified